Free shipping on all orders over $ 500

NSC12

Cat. No. M5235

NSC12 Structure

Synonym: NSC 172285

Size Price Availability Quantity
5mg USD 134 In stock
10mg USD 220 In stock
Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

In vitro: NSC12 inhibits FGF-dependent tumor growth, angiogenesis, and metastases. NSC12 does not affect FGF2/heparin interaction, whereas it inhibits the binding of FGF2 to the immobilized receptor (ID50 ∼30 μM). NSC12 interferes with FGF2/FGFR1 interaction without affecting the ability of the growth factor to interact with heparin or HSPGs. NSC12 also binds immobilized FGF3, FGF4, FGF6, FGF8, FGF16, FGF18, FGF20, and FGF22 with Kd values ranging between ∼16 and ∼120 μM. NSC12 may act as a multi-FGF trap by interacting with all members of the canonical FGF subfamilies. NSC12 hampers FGF23-mediated FGFR1 activation in Klotho-expressing Chinese hamster ovary (CHO) cells. Treatment with NSC12 causes the reduction of the S phase of the cell cycle in all tumor cell lines but LLC cells, in which an accumulation in the S phase is observed. NSC12 inhibits FGFR1, FGFR2, FGFR3, and FGFR4 phosphorylation in CHO cell transfectants. NSC12 inhibits the proliferation of various FGF-dependent murine and human cancer cell lines with no inhibitory effect on HCC827 cancer cells that harbor a tumor-driving mutation of the EGFR TK domain and on FGF-independent cancer cell lines. In vivo: Parenteral and oral delivery of NSC12 inhibits FGFR activation, tumor growth, angiogenesis, and metastasis in FGF-dependent murine and human tumor models. NSC12 causes a significant decrease of tumor weight, tumor cell FGFR1 phosphorylation and proliferation, and tumor CD31+ neovascularization at all the doses tested in the animal models.

Protocol
Cell Experiment
Cell lines KATO Ⅲ cells
Preparation method KATO Ⅲ cells are plated at 104 cells/well in 96 well-plates in RPMI medium plus 1% FBS. After 24 hr cells are treated with different FGFs (30 ng/ml) in the absence or presence of an optimal dose of NSC12 (1.0 or 3.0 μM) or NSC21. After 72 hr the MTT assay is performed according to manufacturer’s instructions. The optical density (OD) is determined using a plate reader at a test wavelength of 595 nm and a reference wavelength of 630 nm.
Concentrations 1.0 or 3.0 μM
Incubation time 72 h
Animal Experiment
Animal models C57BL/6 mice
Formulation DMSO
Dosages from 2.5 to 10 mg/kg
Administration i.p.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 484.52
Formula C24H34F6O3
CAS Number 102586-30-1
Purity >99%
Solubility 96 mg/mL in DMSO
Storage at -20°C
References

Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors.
Castelli R, et al. J Med Chem. 2016 May 26;59(10):4651-63. PMID: 27138345.

Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.
Ronca R, et al. Cancer Cell. 2015 Aug 10;28(2):225-39. PMID: 26267536.

Related FGFR Products
FGF-401

FGF-401 is an inhibitor of FGFR4 extracted from patent WO2015059668A1, compound example 83; has an IC50 of 1.9 nM.

PD-166866 (PD166866)

PD-166866 is a synthetic molecule inhibiting the tyrosin kinase action of FGFR1, shows a very high selectivity towards FGFR1 and inhibits the auto-phosphorylation activity of FGRF1.

BLU-9931

BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively.

H3B-6527

H3B-6527 (H3 Biomedicine) is a highly selective FGFR4 inhibitor with potent antitumour activity in FGF19 amplified cell lines and mice.

BLU-554

BLU-554 is a potent, highly-selective, oral FGFR4 inhibitor with an IC50 value of 5 nM. The IC50s for FGFR1-3 is 624-2203 nM.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: NSC12, NSC 172285 supplier, FGFR, inhibitors

Contact Us
  • Tel: +1-800-660-8580
  • Email: sales@abmole.com
  • Tel: +32 (0)2 738 09 61
  • Email: eu.order@abmole.com

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.